Following the registration of the amendment to the Articles of Association in the Commercial Register, former Darwin AG (ISIN DE000A3C35W0) will now operate under the name Novogenia AG. The name change, approved at the Annual General Meeting on June 26, 2026, is a strategic move to unify the company's market presence and reinforce its focus on its core operating brand.
The Group's operational business and future growth are primarily driven by its wholly owned subsidiary, Novogenia GmbH, which has been active in human genetics for years. Novogenia GmbH develops and sells personalized products based on genetic analysis, and the Novogenia brand represents deep scientific expertise and continuous technological innovation. The renaming aims to standardize the company's brand identity, simplify corporate structure and communication, and create a consistent image across all target groups, including customers, partners, investors, and the capital market.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, stated, "Novogenia has been at the heart of our operational business and our international market presence for many years. By operating under the name Novogenia AG, we are consistently unifying our corporate and brand identities. This enhances the visibility and recognition of our Group while reinforcing our ambition to establish Novogenia as a leading international provider of personalized healthcare and longevity solutions, as well as a strong and recognizable brand in the capital market."
The name change does not affect the company's strategic direction, business model, or operational activities. The stock market listing and existing shareholder rights remain unchanged. For more information, visit https://novogenia.com/novogenia-ag.
